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ABSTRACT

Cancer cells are characterized by their ability to grow and proliferate in rates that far
exceed normal cells by modifying their iron/heme metabolisms to levels higher than normal.
This imbalance of heme biosynthesis can lead to cancer cells having a flux of heme
intermediates to the point where they enter a state called heme-overdrive. Heme-overdrive is a
process unique to a variety of cancers but absent in normal tissues. With this enhanced
production, heme can act as an epigenic regulator for signaling proliferation (18). Through the
novel strategy called ‘bait-and-kill,’ cancer cells will be coerced into a state of heme overdrive
then killed through an iron-dependent, non-apoptotic, regulatory cell death called ferroptosis.
However, cancer cells can vary from each other meaning that their sensitivity to the same
ferroptosis inducer may differ.
The cell lines that were utilized in this research were two erythroleukemic cell lines
K562 and HEL. Both specimens are iron-dependent but have different metabolic networks which
results in as differential sensitivity to ferroptosis. In summation, our research discovered that
heme-overdrive is a common biological strategy expressed exclusively in cancers that enhances
rapid production of heme for rapid proliferation and growth but is vulnerable to ferroptosis; and
utilizing our ‘bait-and-kill’ strategy we can target this unique, and exploitable, vulnerability to
destroy it.
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INTRODUCTION

Our bodies are complex organisms composed of different types of cells that have
differentiated themselves throughout our body for very specific roles that vary depending on
what tissue of which organ they constitute. Except for the brain and heart, the cells that make up
our organs are locked in a constant dance of life and death. For our body to function normally,
our cells need to perform their job without fail this includes when they live and when they are to
die. Programmed cell death is an important function in our body that keeps our organs
functioning optimally by recognizing and eliminating cells that are either dysfunctional or
damaged. The constant, organized, culling of dysfunctional cells allows for new cells to take
their place to keep organs at their peak operating performance and to potentially eliminate cells
that can end up being the cause of various problems within the body, most importantly, cancer.
Unlike normal cells, cancer cells lack any regulative behavior that may control its
growth. This constant need to grow requires cancer cells to intake far more intermediates
required for growth than any other cell by modifying their metabolism to heightened levels, in a
similar way to the Warburg effect of modified glucose metabolisms (14, 15). To proliferate so
rapidly, cancer cells require the rapid readily intake of intermediate components that are essential
for replication, namely heme. Heme is a protein prosthetic group and serves as an essential cofactor for numerous cellular pathways. This rapid intake of heme and iron intermediates results
in cancer cells going into a state called ‘heme-overdrive.’
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Heme overdrive is characterized in cancer cells by enhanced heme flux, the imbalance of
their heme biosynthesis pathway, and the accumulation of porphyrins (16-20). Heme
biosynthesis imbalance a modification that is exploited by cancer cells to increase production of
heme intermediates for rapid cell growth and replication (8). Heme in the case of erythrocytes
becomes an epigenetic regulator for the activation of RAS and oncogenic sequencing for
angiogenesis. Because cancer cells have such a heightened iron/heme metabolism they are
addicted to iron, these cells are far more iron-dependent than any other and are much more
sensitive to iron deficiency (27). From studying the data of numerous diverse cell lines, it is
evident that this state of heme overdrive is a ubiquitous trait in cancer cells. This trait can
potentially be used to terminate cancer cells by inducing a type of non-apoptotic iron-dependent
cell death called ferroptosis.
The challenge with using ferroptosis is that despite the many several regulatory pathways
that can be exploited, all inducers of ferroptosis are very specific to one pathway and will not
work on all cancer cell lines with the same result. Cancers exhibit varying levels of sensitivity to
inducers that depend on the pathway the inducer attacks. This highlights the need for observation
and experimentation with several different inducers to ascertain their efficacy with paired cancer
cell lines to determine the most effective for each. This will be achieved through a process called
‘Bait-and-Kill,’ a two-step process that tests the inducers when the cancer cells are prepared in
similar conditions that are optimal for inducing ferroptosis. Bait-and-kill has the added benefit of
serving as a foundation to simplify the collection of IC50 values for selected ferroptosis inducers
so to in turn have a proper baseline to measure their efficacy with different cancer cell lines.
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PROJECT GOALS

The initial objective of the research is to utilize the pan-cancer state of heme overdrive to
observe and document pathways to induce ferroptosis in a variety of cancer cells. Including
ascertaining the IC50 values of the initial cancer cell lines tested to calculate efficient
concentration values for repeated testing on other cell lines. Furthermore, this will serve to
properly test and develop the bait-and-kill strategy.
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BACKGROUND

3.1 Heme Biosynthesis Pathway
The production of heme is first catalyzed by 5-Aminolevulinate synthase, and exogenous
amino acid that is the first precursor of porphyrin biosynthesis (28, 29). In mammals, ALA is
synthesized by the ALA-synthase enzyme (ALAS) from the amino acid glycine and succinyl
CoA. The genes ALAS1 and ALAS2 code for the housekeeping and erythroid-specific ALAS
isomers that work together to create two of the biochemical pathways in heme biosynthesis
working in conjunction to balance the production so that it meets, and not exceeds, demand of
heme. ALAS1 is the housekeeping promotor that is expressed in every cell, whereas ALAS2 is
the erythroid-specific isomer that is only expressed in developing erythrocytes (16, 32).
Ferrochelatase (FECH) is an enzyme that takes protoporphyrin IX and ferrous (Fe2+) and
produces heme.

Figure 1. Diagram detailing the heme biosynthesis pathway.
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3.2 Ferroptosis
The effect of ferroptosis depends on the cell’s iron metabolism and its lipid metabolism.
Iron is taken into the cell via the TFRC as TF-Fe3+ complex where it is reduced to Fe2+ by
STEAP3. Excess iron is stored as Fe2+ in the unstable iron pool (LIP). The LIP is considered as
free iron to be used for metabolic processes within the cell and usually remain in healthy
amounts due to constant regulating uptake, storage, and release mechanisms maintained by iron
regulatory proteins. If levels are not properly regulated, then the free iron can potentially undergo
reactions that increase the cell’s cytotoxicity leading to ferroptosis.
Iron dependent lipid reactive oxygen species (ROS) accumulation is present in all
pathways of ferroptosis. Poly unsaturated fatty acids (PUFAs) are key elements in ferroptosis as
they are sensitive to lipid peroxidation. In order for PUFAs to transmit a ferroptosis signal, they
must be esterified into membrane phospholipids such as phosphatidylethanolamine (PE) which
contains arachidonic acid or adrenic acid (10, 35).
Poly unsaturated fatty acid (PUFA) peroxides (LOOH) are generated as a naturally
occurring component of the lipid metabolism and is reduced by GPX4 if accumulated towards a
cytotoxic level. If LOOH reacts non-enzymatically with Fe2+ or heme, a potentially toxic
chemical environment for the cell is generated (35).

3.3 5-Aminolevulinate synthase (ALAS)
5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) catalyzes the first and regulatory
reaction step in mammalian heme biosynthesis (28). Two genes, ALAS1 and ALAS2, encode the
housekeeping and erythroid-specific ALAS isoforms, respectively (16). ALAS2 activity along
5

with erythroid iron uptake have determining regulatory roles in heme biosynthesis (7, 34). It is,
in fact, the coordination between iron acquisition, heme biosynthesis and globin synthesis that
makes erythropoiesis possible (7). All examined AML cells (33) require ALAS1, TFRC, and the
heme transporter FLVCR to survive. This suggests a high potential therapeutic value for
targeting cancer heme metabolism (30,31).

3.4 Ferroptosis Inducers
There are many pathways to induce ferroptosis, all either affect iron metabolism or the
lipid metabolism either by inhibiting certain proteins, such as GPX4, or mediating
transmembrane channels such as the VDAC channels of the mitochondria.
RSL3 is an inducer that directly inhibits GPX4, reducing the antioxidant capacity of cells
and accumulating toxic levels of lipid ROS (10).
Erastin directly targets the voltage-dependent anion channels (VDACS) which in turn
inhibits the cysteine-glutamate antiporter complex Xc- (System Xc-) which inhibits the import of
cystine (which reduces to cysteine) a component for GSH synthesis (36). This reduces the levels
of GSH subsequently reducing levels of GPX4 in the cell. Erastin can also induce the autophagic
degradation of ferritin, increasing cellular labile iron. This increase in the LIP triggers IRPIRE to increase synthesis of ferritin to regulate the increasing concentration of free labile iron.
The increase of both free labile iron and the reduced levels of GPX4 puts the cell in immense
oxidative stress to constantly regulate the fluctuating levels in the iron and lipid metabolisms
until the regulatory system is exhausted of GPX4 allowing the accumulation of lipid ROSs which
signal ferroptosis (10).
6

FIN56, a derivative of CIL56, has two approaches to inducing ferroptosis. The first
method is reducing the expression of the GPX4 protein. The second method is when FIN56 binds
to squalene synthase ceasing the production of the CoQ10, an important free-radical scavenging
antioxidant (21). Depleting CoQ10 inhibits the mevalonate (MVA) pathway which
downregulates the synthesis of selenocysteine tRNA, which in turn affects the synthesis of GPX4
and inducing ferroptosis (21).
Artemisinin is a drug that was derived from the Asian plant Artemisia annua and is
mainly used as an antimalarial agent. It is an iron (II) oxide-reactive endoperoxide that
generates ROSs through the process of cleaving its endoperoxide bridge (1). This generation of
ROSs lead to the cells undergoing oxidative stress where the sensitized cancer cell undergoes
ferroptosis by cysteine deprivation and subsequently GPX4 inhibition in a lysosome-dependent,
but autophagy-independent manner (1,33).
CIL56 induces ferroptosis through the accumulation of iron-dependent ROSs. This
pathway of ferroptosis is dependent on the expression of acetyl-CoA carboxylase 1 (ACC1) a
rate-limiting enzyme responsible for the lipogenesis of long chain fatty acids and plays a critical
role in energy storage. The activity of ACC1 sensitizes the cells to a CIL56 induced cell
death. CIL56 is unique in that it can maintain similar efficacy levels of inducing ferroptosis even
at low concentrations. Additionally, CIL56 expressed in higher concentrations induces cell death
that cannot be suppressed (21, 34)
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Table 1. Ferroptosis inducers and their mode of action
Ferroptosis Inducers

Mode of Action

(1S,3R)-RSL3

Directly binds the selenocysteine active site of GPX4

Erastin

Inhibits uptake of cystine through system x c-

FIN56

Reduces expression of GPX4 protein; also binds to and activates
squalene synthase in a GPX4 degradation-independent manner
Iron (II) oxide-reactive endoperoxide that generates ROS

Artemether (ART)
CIL56

Iron-dependent ROS; ferroptosis at low concentrations, and
necrotic, non-suppressible cell death at higher concentrations

3.5 Heme Overdrive
Our study represents the first effort to examine the role of heme biosynthesis in the
context of oncology with tools in forward genetics and biochemical studies. Here, we highlight
the importance of heme in oncogenesis by coining a term ‘heme-overdrive’ i.e. cancers
heightened metabolic dependence on heme flux and imbalanced biosynthesis. ALA-induction
studies indicated the absence of heme overdrive (7).
Additionally, the available clinical surgical data under ALA induction confirms the
absence of heme overdrive in normal tissues because the surgical procedure relies on
fluorescence absent in tissues surrounding tumors (2-6).

3.6 Bait-and-Kill
Bait-and-Kill is a two-step process where our iron dependent cancer cell lines would be
stimulated into heme overdrive by addition of the heme precursor ALA to the cultures. The ALA
‘bait’ induces the accumulation of PPIX to levels equal to a hundred-fold of normal cell
concentrations.
8

Then the ‘kill’ involves the introduction of a ferroptosis inducer into the now ALA sensitized cancer cells forming a lethal heme adduct. This strategy allows us to overcome the
problem of cancers having a range of sensitivities and those that have stress-coping mechanisms.

Figure 2. Bait-and-Kill, ‘Bait’ cancer cells with ALA to induce PPIX accumulations to equate to
a significantly higher concentration compared to the control cells, ‘Kill’ with a ferroptosis
inducer with a lethal heme adduct Artemisinin.
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METHODS

4.1 Differential Sensitivity of K562 and HEL
The cell lines that were used in the experiment were K562 and HEL. They are
erythroleukemia cell lines that both share a dependency on their iron metabolism but have
different pathways for ferroptosis and as such different sensitivities to ferroptosis inducers. K562
is a multipotent stem cell line from human chronic myelogenous leukemia and HEL is an
erythroid progenitor cell line from Acute Erythroid Leukemia (AML-M6) (known for “Acute Di
Guglielmo Syndrome”). The two cell lines share genetic dependencies on iron transport and
heme synthesis but differ in redox stress handling and iron/heme detoxification pathways.

4.1.1 Cell Cultures
K562 and HEL cell were obtained from American Type Culture Collection (Manassas,
VA) and maintained according to the recommended protocol. The cells are thawed in 37°C water
bath for 3 minutes, followed by suspension in complete media comprised of RPMI-1640 media
supplemented with 10% fetal bovine serum, penicillin-streptomycin- amphotericin [10μg/mL],
and L-glutamine [2mM] at 37°C and 5% CO2. The cells were centrifuged at 120 rpm for 5minutes to remove the remnants of the freezing media prior to being added in to the T75 flask.
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A 10 µl cells suspension is stained with trypan blue dye and counted with a
hemocytometer to make sure the cell viability was > 90 %. Additionally, cell cultures were
passed when reaching around 80% confluency. The complete media was stored at 4°C and
warmed to 37°C when added to the culture. K562 and HEL cells were collected at the first,
second, and third passage for freezing. Frozen stocks of K562 and HEL cells were stored in
liquid nitrogen suspended in a 10% DMSO and complete media solution.

4.1.2 Cell Seeding Density and Viability Determination
A stock concentration of K562 cells (12,000 cells/25μl) was used to make two-fold serial
dilutions of 25μl per well in complete RPMI media into 384-well plates (Catalog No. 781091,
Greiner Bio-One). These dilutions were done in triplicates. Initial cell concentrations in the 25μl
media ranged from 6000 to 750 K562 cells per well. Cell proliferation was measured at intervals
of 0, 24, 48, and 72 hours. Number of cells present in each well was counted via hemocytometer
under a microscope using trypan blue for the exclusion of dead cells.
A 10µl cell suspension was used to make a 1:10 dilution (100µl final volume) followed
by the transfer of 50µl to a tube with equal amount 0.4% trypan blue and mixed well. 10µl of the
mix is loaded on to a hemocytometer to count viable cells (unstained) under an inverted
microscope. If the cell viability was determined to be >90% the cell line was inoculated into a
384-well plate, in specific concentrations, returned to the incubator to grow for ~48 hours, and
then were quickly reviewed for possible abnormalities before being used in the experimentations.
These 384-well plates inoculated with the viable cell lines were used to initially test the per-wellviability of a luminescence-based assay called ATPlite one-step solution (PerkinElmer).
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The ATPlite 1step assay is an adenosine triphosphate (ATP) monitoring assay that
measures cell viability through luminescence emission generated by the reaction of D-luciferin
with ATP. ATP is the primary energy molecule that drives most biological functions including
respiration, it is found in and around living organisms and conversely absent otherwise. When Dluciferin reacts with ATP, the reaction produces light for approximately 30 minutes. The emitted
light is proportional to the concentration of viable cells. In accordance with the manufacturer’s
protocol, luminescence readings were measured in a CLARIOstar Plus (multi-mode microplate
reader).
To properly utilize the assay, the substrate vial, buffer solution, and our inoculated 384well plates must be brought to room temperature, which takes approximately 30 minutes. Once
all three components are room temperature, the ATPlite 1step solution can be reconstituted and
immediately inoculated into the 384-well plate. A multichannel pipette was used to add 25 µl of
the ATPlite 1step solution, to the 384-well plate.
Additionally, an ATP standard curve assay was performed on the same plate by preparing
some wells with 10-fold serial dilution series of ATP in culture medium (1μM to 1pM). Then the
plate was shaken for 2 minutes at 1,100 rpm in a IKA MS 3 digital MIXER (IKA, Staufen,
Germany) as recommended by the manufacturer. As stated by the manufacturer, black 384-well
plates show minimal plate phosphorescence which allows us to measure luminescence
immediately after shaking. Luminescence was measured in a ClarioStar plate reader (BMG
LabTech).
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4.2 CellTiter-Glo 2.0 vs ATPlite 1step Luminescent Cell Viability Assay
A major problem with the cell viability assays is that they are relatively expensive per
well and are not suitable for long term storage once the lyophilized substrate and buffer were
mixed. Which means that the best one for our interests needs to be sensitive and have the longest
storage life, which is why we investigated another similar luminescence assay CellTiter-Glo 2.0.
Freshly prepared ATPlite 1step is stable for 8 hours at 20 °C, 48 hours at 4 °C, and for
1 month at -80 °C. While fresh CellTiter-Glo 2.0 maintains >85% activity when stored at 4°C for
2 months. So, we tested CellTiter-Glo® 2.0 (Promega) and ATPlite 1step (PerkinElmer) for
differences in measuring cell viability. We used a 96-well plate seeded with K562 and HEL cell
lines in 100µl of complete media in a series of 10-fold serial dilutions starting from 6000
cells/well to 46 cells/well, by adding equal volume of CellTiter-Glo 2.0 and ATPlite 1step
solution to each well. Then the plate was shaken for 2 minutes at 700 rpm in an IKA MS 3
digital MIXER (IKA, Staufen, Germany) as recommended by the manufacturer. Luminescence
was measured directly after shaking and data were captured using a ClarioStar plate reader
(BMG LabTech).

4.3 Ferroptosis Inducer Concentration Determination

384-well plates were prepared by adding 10 µl of complete media then placed in the
incubator to equilibrate to 37 °C. The plates are seeded with either K562 or HEL cell lines
(with >90% cell viability) by adding 10µl media containing 300 cells/µl in each well, bringing
the total volume to 20µl. Now the cells are left to incubate for another 48 hours in the incubator,
to reach the desired cell density, before adding in the compounds.
13

A 384-well compound plate is prepared with all the inducers stored in -80°C at 10mM
concentration (prepared ahead by diluting the compounds in DMSO). The drugs are serial diluted
in complete media in a 384 well cell culture plate ranging from the concentration of 1mM to 7.6
E+06mM using a multichannel pipette.

Figure 3. Master Prep plate #1 – Compound serial dilution and 1% DMSO reagent preparation

Figure 4. Prep plate #2
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The compounds are transferred in to 384 well plate containing cells using a multichannel
pipette and care in taken to make sure the tips are discarded after each transfer on the compound,
to prevent cross contamination.
After the addition of the compounds, the cells are incubated for another 24 hours in the
incubator. Now an equal volume of CellTiter-Glo® 2.0 solution is added to the wells. Noe the
plate is shaken in an IKA MS 3 digital MIXER (IKA, Staufen, Germany) for 2 minutes at 1100
rpm as recommended by the manufacturer. Luminescence was measured directly after shaking
and data were captured using a ClarioStar plus plate reader (BMG LabTech).

Figure 5. Bait-and-Kill setup timeline, (a) ferroptosis inducers, (b) 0.5 mM ALA treatment
followed by ferroptosis inducer addition.
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RESULTS AND DISCUSSION

5.1 Luminescent Signal and Cell Number Using the ATPlite 1step Assay

The relationship between luminescence measured with the ATPlite 1step Assay and the
K562 cells seeded in 384-well plate in complete media was determined by making serial twofold
dilutions. The dilution range started from 6000 to 750 K562 cells per well. Figure 6 shows the
relationship between ATPlite 1step assay luminescence values and the K562 cell count per well.

Figure 6. ATPlite 1step serial dilution luminescence signal. The error bars depict the 97%
confidence interval.
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The error bars depict the 97% confidence interval of two replicates for each cell
concentration with an R2 of 0.9706. The background luminescent signal from medium without
cells is 30x lower than the luminescent signal emitted from the lowest concentration
(~750 cells/251μL/well), indicating that there is not a significant deviance from linearity between
the luminescent signal and the number of cells.

5.2 CellTiter-Glo® 2.0 vs ATPlite 1step Luminescent Cell Viability Assay

Figure 7. CellTiter-Glo 2.0 vs ATPlite 1step Luminescent Cell Viability Assay

The test comparing CellTiter-Glo 2.0 to the ATPlite 1step assay was performed by
inoculating the assays into a 96-well plate that contained both K562 and HEL cell lines. The
K562 and HEL cell lines were seeded into 2 designated columns in a 96-well plate and serially
diluted from a starting cell population of 20,000cells/well in the first row to 156 cells/well in the
final row. Both assays were each inoculated into a pair of 2 adjacent columns that contained
K562 and HEL in complete media.
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The plate was shaken for 2 minutes at 700 rpm in a IKA MS 3 digital MIXER (IKA,
Staufen, Germany) as recommended by the manufacturer. Both white 96-well plates were dark
adapted (to remove any white phosphorescence) for 10 minutes after which luminescence was
measured with a ClarioStar plus plate reader (BMG LabTech).
The results, shown in Figure 7, indicate that their cell viability efficacy was nearly
identical. These results allowed us to firmly affirm the replacement of the ATPlite 1step assay
with CellTiter-Glo 2.0 without the risk of less accurate cell viability readings coupled with the
main fact that CellTiter-Glo 2.0 can be stored for twice as long as ATPlite and still retain >85%
activity.

5.3 Ferroptosis Inducers IC50 Determination
The mechanism of action of ferroptosis inhibitors used in the current study is outlined in
Table 1. The half maximal inhibitory concentrations (IC50) of RSL3, Erastin, FIN56, ART and
CIL56 with K562 and HEL cells were determined by dispensing the inducers in concentrations
of 20µl, 15µl, and 5µl against cell populations in 100µl of complete media that had undergone a
series of 10-fold dilutions starting from 6000 cells/well to 750 cells/well.
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Figure 8. K562 proliferation curves with ferroptosis inducers added at various concentrations.
Cell proliferation was measured after 24 hours of culture with CellTiter-Glo 2.0 reagent to
quantify cellular ATP. Both RSL3 and CIL56 worked on K562, while CIL56 showed to be
working at lower concentrations than RSL3.

Figure 9. HEL proliferation curves with ferroptosis inducers added at various concentrations.
Cell proliferation was measured after 24 hours of culture with CellTiter-Glo 2.0 reagent to
quantify cellular ATP. RSL3 showed to be much more potent than CIL56. Because of the linear
nature of the result, we were unable to get the R² value to fit the curve.
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5.4 Ferroptosis Inducers with ALA IC50 Determination
Cell proliferation was measured after a 48-hour incubation period utilizing the CellTiterGlo 2.0 reagent to quantify cellular ATP. Both cell lines were treated with ALA at 0.5mM. Both
RSL3 and CIL56 showed similar potency as with the untreated. This is possibly due to the halflife of ALA (one hour), and the timing of the drug inoculation in the culture. It can be reasonably
inferred that a shorter time window between the sensitization with ALA to the inoculation of the
inducer into the cell cultures may yield the increased (and differentially significant) effect.

Figure 10. K562 proliferation curves with ferroptosis inducers added at various concentrations
with 0.5 mM ALA. Cell proliferation was measured after 48 hours of culture with CellTiter-Glo
2.0 reagent to quantify cellular ATP.
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Figure 11. HEL proliferation curves with ferroptosis inducers added at various concentrations
with 0.5 mM ALA. Cell proliferation was measured after 48 hours of culture with CellTiter-Glo
2.0 reagent to quantify cellular ATP. RSL3 wiped out the whole cell population even at the
lowest inducer concentration of 0.0010 µM.

Figure 12. HEL proliferation curves with the RSL3 inducer when the cancer cell lines were
sensitized with ALA and without ALA sensitization.
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CONCLUSION

This research explored the concept of heme-overdrive a pan-cancer unique characteristic
wherein iron-dependent cancer cells modified their heme biosynthesis pathways to enhance the
production of heme to extreme levels for the ability to rapidly grow and proliferate. Further
observations highlighted a potential weakness to ferroptosis if it is induced through the right
pathway. Because there are multiple pathways to induce ferroptosis, we devised a stratagem
dubbed ‘bait-and-kill’ an idea that cancer cells in a state of heme-overdrive can be reliably
eliminated by ferroptosis by the correct inducer. This experiment would be performed on two
erythroleukemic cell lines K562 and HEL both are iron-dependent but have different
biosynthesis pathways and as such differing sensitivities to ferroptosis inducers.
The initial ferroptosis inducers were limited to 5 which included artemisinin, erastin,
FIN56, and CIL56 each having unique ways to disrupt iron homeostasis or lipid peroxidation.
Then testing revolved around ascertaining the IC50 value of each inducer for both cell lines. To
measure the death of the cells, we initially adopted the ATPlite 1step assay, an ATP monitoring
luminescence assay that emits light based on the ATP (and correspondingly) reflects the number
of viable/living cells left. This was later exchanged out for CellTiter-Glo 2.0 based on a having
twice the storage time.
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When everything was ready to begin ferroptosis induction testing, we performed the
experiments two sets of 384-well plates, the difference between the sets was that one was given
ALA (a heme precursor) 24 hours prior to testing while the other set did not. This test gave us
the potential to observe if heme-overdrive could more easily induce ferroptosis.
The results of the experiment proved our ‘bait-and-kill’ method, but problems were also
discovered. Namely, the potential of the one-hour half-life of ALA affecting coupled with the
24-hour time frame between giving ALA and inducing ferroptosis. This unseen factor led to
some results looking identical, while others (namely with RSL3) showed the complete
eradication of the entire cell line even at the lowest concentration of the inducer.
This initial research excursion yielded invaluable data including the proof of concept for
the ‘bait-and-kill’ stratagem and that ferroptosis looks to be a potential for the creation of novel
cancer therapies.
Future experiments will include testing CRISPR/KO mutants of both K562 and HEL cell
lines with knockouts of ALAS1, ALAS2, and FECH to observe how this may affect the
biosynthesis pathway and inducing ferroptosis. Further inducers will also be tested such as
deferoxamine (mesylate). Another method of experiments will involve utilizing ferroptosis
inhibitors, such as ferrostatin-1, to ‘rescue’ cancer cells against ferroptosis.
This experimentation with ‘bait-and-kill’ has the potential to be a novel cancer therapy
that can be tailored to choosing the most effective inducer against a cancer cell line. There is so
much that can be done with it with this first step as our starting line.
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